Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BDTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Silevertinib | Non-Small Cell Lung Cancer | Phase 1/2 · NCT05256290 | Active not recruiting |
| Use autologous cSVF + MSCs (cryo) for… | Autism Spectrum Disorder | Phase 1/2 · NCT07546942 | Enrolling by invitation |
| Tuxobertinib (BDTX-189) | Solid Tumor | Phase 1 · NCT04209465 | Terminated |
| Liberase Enzyme (Roche) | Pulmonary Alveolar Proteinosis | Early Phase 1 · NCT04326036 | Unknown |
Also used in these trials (approved or third-party drugs, not BDTX's own candidates): Temozolomide, Azathioprine, Carfilzomib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BDTX holds $102M in cash and short-term investments (as of Sep 30, 2026) and burns about $8.2M/quarter from operations, an estimated runway of 37.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 15 · Low
As of September 30, 2026, we had cash, cash equivalents and investments of approximately $102.0 million, which we believe will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BDTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Ali Behbahani Director · +101,100 options |
Insider | 4,558,993 | 7.93% | 2026-09-18 |
| Versant Venture Capital VI, L.P. 10% owner |
Insider | 4,548,481 | 7.91% | 2024-08-28 |
| NEA Management Company, LLC | Institution (13F) | 4,448,757 | 7.74% | 2026-06-30 |
| T. Rowe Price Investment Management, Inc | Institution (13G, 5%+) | 4,028,202 | 7.01% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 3,838,590 | 6.68% | 2026-06-30 |
| Growth N V Biotech 10% owner |
Insider | 2,733,547 | 4.76% | 2025-03-19 |
| Acadian Asset Management. LLC | Institution (13F) | 2,348,651 | 4.09% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 2,125,270 | 3.70% | 2026-06-30 |
| Renaissance Technologies, LLC | Institution (13F) | 1,962,394 | 3.41% | 2026-06-30 |
| Defilade Capital Management, L.P. | Institution (13F) | 1,674,999 | 2.91% | 2026-06-30 |
| Dimensional Fund Advisors LP | Institution (13F) | 1,365,384 | 2.38% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 1,218,171 | 2.12% | 2026-06-30 |
Share count 57,468,255 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-18 filed 2026-09-21 |
Raman Prakash |
Award (A) | 6,801 | $1.93 | 51,840 |
| 2026-09-18 filed 2026-09-21 |
Behbahani Ali |
Award (A) | 7,707 | $1.93 | 110,236 |
| 2026-06-19 filed 2026-06-22 |
Raman Prakash |
Award (A) | 7,907 | $1.66 | 45,039 |
| 2026-06-19 filed 2026-06-22 |
Behbahani Ali |
Award (A) | 8,961 | $1.66 | 102,529 |
| 2026-03-20 filed 2026-03-20 |
Raman Prakash |
Award (A) | 6,105 | $2.15 | 37,132 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BDTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →